BSE filing, NSE: MACINTR. Summary written from the filing by ALFA Finder's alert engine.
Astal Laboratories Ltd: key numbers
- Share price
- ₹64.10
- Market cap
- ₹270.6 Cr
- Revenue (annual)
- ₹156.0 Cr
- Net profit (annual)
- ₹8.12 Cr
- P/E (TTM)
- 27.8×Sector 36.4×
- Promoter holding
- 4.59%+0.06% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Astal Laboratories Ltd
All →Astal Laboratories Other Announcement
Astal Laboratories' material subsidiary, Sriven Pharmachem India, appointed new Internal, Cost, and Secretarial Auditors. The appointments were approved during the subsidiary's board meeting on September 28, 2026.
Astal Laboratories Management Change
Astal Laboratories Limited has appointed Ms. Ambika Kedia as Company Secretary of its material wholly-owned subsidiary, Sriven Pharmachem India Private Limited. The appointment is effective from September 28, 2026.
Astal Laboratories Annual General Meeting
Astal Laboratories held its 33rd Annual General Meeting on September 29, 2026. Members transacted business regarding financial statements and the re-appointment of a director.
Astal Laboratories Promoter Buying: ₹0.2 Cr
Promoter Aceso Research Labs LLP acquired 25,417 equity shares of Astal Laboratories Ltd via market purchase, increasing their stake from 4.53% to 4.59%.
- Value
- ₹0.20 Cr
- Promoter stake change
- +0.06%
Astal Laboratories Promoter Buying
Astal Laboratories' promoter ACESO Research Labs LLP bought equity shares on BSE under a SEBI PIT disclosure. The open-market purchase signals promoter confidence.
Astal Laboratories Annual Report
Astal Laboratories has submitted its Annual Report for the financial year 2025-26 and the notice for its 33rd Annual General Meeting scheduled for September 29, 2026.
Other other announcement announcements
All →Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.